Cartalax (20 mg Vial) Dosage Protocol

Cartalax Dosage Chart

Cartalax is dosed at 2 mg–5 mg daily via subcutaneous injection in educational protocols. A 20 mg vial reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research and educational use only.

Example daily range: 2,000–5,000 mcg once daily (gradual titration).
Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long-term; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Cartalax is a synthetic tripeptide bioregulator (Ala‑Glu‑Asp; sequence “AED”) developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Preclinical studies indicate it may modulate fibroblast proliferation markers (Ki‑67), reduce pro‑apoptotic signaling (p53, caspase‑3), and support extracellular matrix homeostasis.
Note: Published human posology for subcutaneous Cartalax is limited; this framework extrapolates from available preclinical and observational data for educational purposes only.

Educational framework for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Route & Frequency: Subcutaneous, once daily. Evidence note: Specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance.

Phase	Daily Dose (mg)	Units (per injection) (mL)
Weeks 1–2	2,000 mcg (2.0 mg)	30 units (0.30 mL)
Weeks 3–4	3,000 mcg (3.0 mg)	45 units (0.45 mL)
Weeks 5–8	4,000 mcg (4.0 mg)	60 units (0.60 mL)
Weeks 9–12	5,000 mcg (5.0 mg)	75 units (0.75 mL)

This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection volumes within typical SC tolerability parameters (≤~1.0 mL per site).

Reconstitution Steps

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on an 8–16 week daily protocol with gradual titration (average ~3.5 mg/day).

Concise summary of the once‑daily regimen.

Goal: Support connective-tissue homeostasis and fibroblast function based on preclinical bioregulator research.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 2,000–5,000 mcg daily with gradual titration.
Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
Storage: Lyophilized: refrigerate or freeze; reconstituted: refrigerate; avoid repeated freeze–thaw.

Suggested daily titration approach.

Start: 2,000 mcg daily; increase by ~1,000 mcg every 2 weeks as tolerated.
Target: 4,000–5,000 mcg daily by Weeks 5–12.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Any consistent time; rotate injection sites.

Proper storage preserves peptide quality.

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
Evidence caveat: Published human clinical trial data for subcutaneous Cartalax is limited; this protocol extrapolates from preclinical studies and standard peptide handling practices.

Cartalax (Ala‑Glu‑Asp) is classified among the Khavinson bioregulatory peptides—ultrashort peptides that may interact with DNA and modulate gene expression at nanomolar concentrations. The peptide sequence corresponds to a motif found in the alpha‑1 chain of type XI collagen, a structural protein important for cartilage integrity. In preclinical fibroblast and chondrocyte culture models, Cartalax has been reported to upregulate Ki‑67 (a proliferation marker), increase SIRT‑1/SIRT‑6 expression, reduce p53 and caspase‑3 activity (pro‑apoptotic signals), and inhibit MMP‑9 synthesis (an enzyme linked to extracellular matrix degradation).

Observations from preclinical literature.

May support fibroblast proliferation and reduce markers of cellular senescence in aged cell cultures.
Preclinical data suggest modulation of extracellular matrix homeostasis via MMP‑9 inhibition and collagen‑related gene expression.
General tolerability: Khavinson bioregulator peptides have been described as well tolerated in observational settings; occasional mild injection‑site reactions (redness, itch) may occur with subcutaneous administration.
Limitations: No large‑scale human RCTs; most data derive from in vitro or rodent models.

Complementary strategies for best outcomes.

General subcutaneous guidance from clinical best‑practice resources.

We recommend Vitality Labs for high-purity 5-Amino-1MQ (50 mg).

Why Vitality Labs Peptides?

This content is for educational purposes only and is not medical advice.

Neuroendocrinology Letters (2002)

— Khavinson VK. Peptides and Ageing. Overview of bioregulatory peptide development and geroprotective mechanisms.

Bulletin of Experimental Biology and Medicine (2016)

— Lin’kova NS et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. AED peptide effects on Ki‑67, CD98hc, caspase‑3, and MMP‑9.

Bulletin of Experimental Biology and Medicine (2014)

— Khavinson VK et al. Peptides regulate the expression of signaling molecules in kidney cell cultures during in vitro aging (p53, p16, SIRT‑6).

The Lancet (2021)

— Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg dose over 26 weeks

Molecular Biology Reports (2020)

— Ashapkin V, Khavinson V et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

International Journal of Molecular Sciences (2023)

— Linkova N, Khavinson V et al. Peptide Regulation of Chondrogenic Stem Cell Differentiation.

Advances in Gerontology (2020)

— Khavinson VK, Linkova NS et al. Short peptides: regulation of skin function during aging (collagen, SIRT‑1/‑6, MMP regulation).

PubChem

— Compound summary for Cartalax (AED peptide; CID 87815447): molecular formula C₁₂H₁₉N₃O₈, MW 333.29.

CDC

— Vaccine administration: subcutaneous route (angle/site; no aspiration).

Advances in Therapy (PubMed)

— Subcutaneous injection factors and tolerability; practical volume considerations.

StatPearls (NCBI Bookshelf)

— Medication routes of administration; cautions for large single‑site SC volumes.

— Handling and Storage Guidelines for Peptides (lyophilized and reconstituted stability).

NCBI Bookshelf

— Best practices for injection (asepsis, preparation, and administration).

Vitality Lab Peptides

— Cartalax (20 mg) product page (quality and batch documentation).